Data_Sheet_1_The Applicability of ADA, AFU, and LAC in the Early Diagnosis and Disease Risk Assessment of Hepatitis B-Associated Liver Cirrhosis and Hepatocellular Carcinoma.docx

Objective: This study aimed to evaluate the applicability of adenosine deaminase (ADA), α-l-fucosidase (AFU), lactic acid (LAC), and their combined detection in the early diagnosis of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC).Methods: A retrospective analysis of hepatitis B-positive liver disease patients admitted between 2015 and 2020 was conducted. The receiver operating characteristic (ROC) curve was used to determine the diagnostic value of each indicator in LC and HCC, and binary logistic regression analysis was performed to determine the factors and risks related to the occurrence of the two conditions.Results: The levels of ADA, AFU, and LAC were significantly increased in patients with CHB, LC, and HCC (p < 0.05). The ROC curve showed that the sensitivity and specificity of ADA, AFU, LAC, and their combined detection in the CHB and LC groups as well as in the LC and HCC groups reflected different degrees of clinical value. In the CHB and LC groups, the adjusted odds ratio (OR) values of ADA, AFU, and LAC among patients in the high-level group were 3.218, 1.859, and 11.474, respectively, when the median was considered the cutoff point. When quartiles were considered the cutoff point, the OR risk values of the adjusted levels of ADA, AFU, and LAC were higher than those of the lowest-level group (Q1) (p < 0.05). In the LC and HCC groups, the adjusted OR values of ADA, AFU, and LAC among patients in the high-level group were 0.967, 2.365, and 38.368, respectively. When quartiles were considered the cutoff point, the OR risk values of AFU and LAC levels were higher than those of the lowest-level group (Q1) (p < 0.05).Conclusion: ADA, AFU, and LAC demonstrated good value in the early diagnosis of LC and HCC. The combined detection of ADA+AFU+LAC is more effective than single detection for the early diagnosis of the two conditions. ADA, AFU, and LAC can serve as risk predictors of LC, while AFU and LAC can be considered early risk predictors of HCC.

本研究旨在评估腺苷脱氨酶（ADA）、α-岩藻糖苷酶（AFU）、乳酸（LAC）及其联合检测在慢性乙型肝炎（CHB）、肝硬变（LC）和肝细胞癌（HCC）早期诊断中的适用性。研究方法：对2015年至2020年间收治的乙型肝炎阳性肝病患者的病例进行了回顾性分析。采用受试者工作特征（ROC）曲线确定每个指标在LC和HCC诊断中的价值，并通过二元逻辑回归分析确定与这两种疾病发生相关的因素和风险。研究结果：在CHB、LC和HCC患者中，ADA、AFU和LAC的水平均显著升高（p < 0.05）。ROC曲线显示，在CHB和LC组以及LC和HCC组中，ADA、AFU、LAC及其联合检测的敏感性和特异性反映了不同程度的临床价值。在CHB和LC组中，当以中位数作为截断点时，高水平组的ADA、AFU和LAC的调整比值比（OR）值分别为3.218、1.859和11.474。当以四分位数作为截断点时，ADA、AFU和LAC调整水平的OR风险值高于最低水平组（Q1）（p < 0.05）。在LC和HCC组中，高水平组的ADA、AFU和LAC的调整OR值分别为0.967、2.365和38.368。当以四分位数作为截断点时，AFU和LAC水平的OR风险值高于最低水平组（Q1）（p < 0.05）。结论：ADA、AFU和LAC在LC和HCC的早期诊断中显示出良好的价值。ADA+AFU+LAC的联合检测比单次检测对两种疾病的早期诊断更为有效。ADA、AFU和LAC可以作为LC的风险预测因子，而AFU和LAC可被视为HCC的早期风险预测因子。